Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A combination therapy consisting of clobetasol propionate, a super-high potency topical corticosteroid, and mucopolysaccharide polysulfate (MPS), a moisturizing ingredient. Studies have shown that MPS can improve tight junction barrier impairment induced by clobetasol propionate. This combination may help delay relapses in atopic dermatitis by maintaining skin barrier function while providing anti-inflammatory effects. Clobetasol propionate works by activating natural substances in the skin to reduce swelling, redness, and itching, while MPS appears to protect the tight junction barrier function in the skin.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on clobetasol propionate + mucopolysaccharide polysulfate.